Neuro-Oncology News

Manmeet Ahluwalia, MD, director of the Brain Metastases Research Program at the Cleveland Clinic and neuro-oncology section editor for HemOnc Today, discusses the promise of immune-based therapies in patients diagnosed with brain metastases.

First-line crizotinib provided better intracranial disease control than chemotherapy for patients with advanced ALK-positive non–small cell lung cancer who had treated brain metastases, according to results of the phase 3 PROFILE 1014 study.

Patients with cancer who undergo chemotherapy may be at elevated risk for a new primary cancer several years later.

Previous investigations conducted by the founders of the linear no-threshold model with respect to genetic effects and carcinogenesis represent “one of the greatest misapprehensions and oversight failures within the scientific research community,” according to authors of a study review published in American Journal of Clinical Oncology.

An assessment tool comprised of clinically relevant questions and specific treatment information accurately predicted risk for chemotherapy toxicity in a majority of older patients with cancer, according to the results of a validation study.

The degree to which extent of resection served as a prognostic marker for patients with medulloblastoma may heavily depend on molecular subgroup affiliation, according to the results of an integrated clinical and molecular analysis.

Male survivors of childhood cancer diagnosed before age 25 years appeared less likely to have children and more likely to require assisted reproduction than men who did not have cancer, according to results of a national cohort study.

A single standard CT scan may increase the risk for fatal cancer in one of every 2,000 patients, according to FDA data.

Patients treated in phase 1 trials designed with a biomarker-based approach for treatment selection demonstrated higher response rates and longer PFS, according to results of a meta-analysis scheduled for presentation at the ASCO Annual Meeting.

The U.S. House Energy Subcommittee on Health today held a hearing to offer doctor and patient perspectives on planned changes to the Medicare Part B drug reimbursement model.